Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Lexicon Pharmaceuticals Stories

2013-06-24 08:28:10

LX2761 Acts Locally in GI Tract to Inhibit Sodium Glucose Transporter 1 THE WOODLANDS, Texas, June 24, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, presented the first publication of data on LX2761 at the 73(rd) Scientific Sessions of the American Diabetes Association (ADA) in Chicago, on June 23, 2013. David Powell, M.D., Lexicon's senior vice president of...

2013-06-24 08:27:42

THE WOODLANDS, Texas, June 24, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, delivered two oral and two poster presentations on LX4211 at the 73(rd) Scientific Sessions of the American Diabetes Association (ADA) in Chicago, on June 23, 2013. Pablo Lapuerta, M.D., Lexicon's executive vice president, clinical development and chief medical officer, delivered an oral...

2013-06-18 08:29:52

THE WOODLANDS, Texas, June 18, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that John Northcott has joined the company as its vice president of marketing, commercial strategy, and operations. Mr. Northcott brings extensive commercial experience to Lexicon, including both pre-launch planning and on-market commercialization across a variety of therapeutic areas....

2013-06-07 08:24:09

THE WOODLANDS, Texas, June 7, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the Goldman Sachs Global Healthcare Conference on Wednesday, June 12, at 2:40 PM PT in Rancho Palos Verdes, California. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones. A webcast of the presentation will be available through Lexicon´s website at www.lexpharma.com. An archived version...

2013-05-31 08:23:58

THE WOODLANDS, Texas, May 31, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Arthur Sands, M.D., Ph.D., president and chief executive officer, will present at the Jefferies Global Healthcare Conference on Tuesday, June 4, at 9:00 AM ET in New York City. Dr. Sands will provide an overview of Lexicon's clinical development programs and milestones. A webcast of the presentation will be available through Lexicon's website at...

2013-05-28 08:27:45

THE WOODLANDS, Texas, May 28, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the Deutsche Bank dbAccess Healthcare Conference on Wednesday, May 29, at 2:10 PM ET in Boston. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones. A webcast of the presentation will be available through Lexicon's website at www.lexpharma.com. An archived version of the presentation will be...

2013-05-13 08:28:06

THE WOODLANDS, Texas, May 13, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Arthur Sands, M.D., Ph.D., president and chief executive officer, will present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, at 3:00 PM PDT (6:00 PM EDT) in Las Vegas, Nevada. Dr. Sands will provide an overview of Lexicon's clinical development programs and milestones. A webcast of the presentation will be available through...

2013-05-10 08:24:14

THE WOODLANDS, Texas, May 10, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it is progressing into the placebo-controlled portion of its Phase 2 clinical trial of LX4211 in patients with type 1 diabetes, having successfully completed the open-label, pioneer portion of the trial. LX4211 is an investigational, oral, dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2). The pioneer phase of the study was designed to gain important...

2013-05-10 08:24:10

Conference Call and Webcast at 11:00 a.m. Eastern Time THE WOODLANDS, Texas, May 10, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2013. "In the first quarter of 2013, we continued to progress our clinical pipeline on multiple fronts. Most...

2013-04-25 08:33:12

THE WOODLANDS, Texas, April 25, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Arthur Sands, M.D., Ph.D., president and chief executive officer, will present at the Needham Healthcare Conference on Tuesday, April 30, at 2:20 PM EST in New York City. Dr. Sands will provide an overview of Lexicon's clinical development programs and milestones. A webcast of the presentation will be available through Lexicon's website at www.lexpharma.com. An...